[A20-96] Ozanimod (multiple sclerosis) - Addendum to Commission A20-59

Last updated 07.01.2021

Project no.:
A20-96

Commission:
Commission awarded on 25.11.2020 by the Federal Joint Committee (G-BA).

Report type:
Addendum

Status:
Commission completed

Department/Division:
Drug Assessment

Topic:
Head and nerves

Indication:

Adults with relapsing remitting multiple sclerosis (RRMS)

Result of dossier assessment:

Treatment-naive patients or patients whose RRMS is not highly active under disease-modifying therapy: unchanged (proof of considerable added benefit). Highly active RRMS despite therapy for which switch within the basic therapy is an option: now proof of major added benefit for men; for women: proof of considerable added benefit.

Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

informedhealth.org logo Accompanying information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.

Federal Joint Committee (G-BA)

07.01.2021 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form